RECIP 1.0 的临床实施
本文综述了针对前列腺癌 PSMA PET/CT 治疗反应评估的 RECIP 1.0 标准的临床实施。RECIP 1.0 基于 PSMA 阳性总肿瘤体积变化和新病灶出现进行分层,具有预后价值,视觉法提升可行性,但肿瘤分割耗时和协议差异仍是挑战,AI 工具有望简化实施。
要点
- RECIP 1.0 是首个基于 PSMA PET 的循证治疗反应评估框架。
- RECIP 1.0 可分层为完全缓解、部分缓解、稳定疾病或进展性疾病。
- 视觉 RECIP 法与定量软件分割一致性极好,提升常规实践可行性。
核心结论
- RECIP 1.0 为 PSMA 靶向诊疗中的治疗反应评估提供了稳健且具有临床意义的框架。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- RECIP 1.0 整合 PSMA 阳性总肿瘤体积变化和新病灶出现,可分层为完全缓解、部分缓解、稳定疾病或进展性疾病。
- RECIP 1.0 对总生存和无进展生存显示出强预后价值。
- 视觉 RECIP 方法与定量软件分割显示出极好一致性。
- 肿瘤分割劳动强度大和成像协议间差异是实施挑战,AI 自动化工具有望简化流程。
关键数值与推荐
- 传统工具如 PSA 动力学、CT、骨扫描及 PCWG3 或 RECIST 等复合标准受 PSA 闪烁现象、无法评估骨-only 疾病及对早期转移变化不敏感的限制。
临床怎么用
- RECIP 1.0 支持标准化报告,对临床试验至关重要。
- 视觉 RECIP 方法增强常规实践可行性,与定量软件分割一致性极好。
局限性
- 肿瘤分割劳动强度大。
- 成像协议间存在变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer remains a major global health burden, and the integration of PSMA-targeted PET imaging and radioligand therapy has transformed diagnostic and therapeutic strategies for advanced disease. Traditional response assessment tools-such as PSA kinetics, CT, bone scans, and composite criteria like PCWG3 or RECIST-are limited by PSA flare phenomena, inability to evaluate bone-only disease, and lack of sensitivity for early metastatic changes. To address these limitations, the Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) was developed as the first evidence-based framework leveraging PSMA PET imaging for treatment response evaluation. RECIP 1.0 incorporates changes in PSMA-positive total tumour volume and the appearance of new lesions, enabling stratification into complete response, partial response, stable disease, or progressive disease. It has demonstrated strong prognostic value for overall and progression-free survival and supports standardized reporting essential for clinical trials. A visual RECIP method further enhances feasibility in routine practice, showing excellent concordance with quantitative software-based segmentation. Although challenges remain, particularly the labor-intensive nature of tumour segmentation and variability across imaging protocols emerging AI-based automated tools are poised to streamline RECIP implementation. As PSMA-based theranostics continue to expand, RECIP 1.0 offers a robust and clinically meaningful framework for response assessment.
引用
- Sen I, Malik D, Thakral P, et al. Clinical implementation of RECIP 1.0. Semin Nucl Med. 2026. PMID: 41519653. doi:10.1053/j.semnuclmed.2025.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。